- Conditions
- Advanced Malignant Solid Neoplasm
- Interventions
- CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration
- Biological · Drug
- Lead sponsor
- Tianhong Li
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc Clear all
- Conditions
- Healthy Volunteers
- Interventions
- Efprezimod alfa, Saline
- Biological · Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Metastatic Melanoma
- Interventions
- CD24Fc, Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Interventions
- Efprezimod alfa, Placebo, Methotrexate, Tacrolimus
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more
- Conditions
- Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
- Interventions
- Efprezimod alfa, Methotrexate, Tacrolimus, Placebo
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more
- Conditions
- HIV Infections, Dyslipidemias
- Interventions
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Efprezimod alfa, Placebo
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more